These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 10535436)

  • 1. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
    Friedberg M; Saffran B; Stinson TJ; Nelson W; Bennett CL
    JAMA; 1999 Oct; 282(15):1453-7. PubMed ID: 10535436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflict of interest and cost-effectiveness analysis.
    Krimsky S
    JAMA; 1999 Oct; 282(15):1474-5. PubMed ID: 10535440
    [No Abstract]   [Full Text] [Related]  

  • 3. Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC.
    Gagnon JP
    JAMA; 2000 Mar; 283(11):1423; author reply 1424. PubMed ID: 10732925
    [No Abstract]   [Full Text] [Related]  

  • 4. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
    Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
    Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial relationships in economic analyses of targeted therapies in oncology.
    Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
    J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sources of bias in the economic analysis of new drugs.
    Rakatansky H
    JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732928
    [No Abstract]   [Full Text] [Related]  

  • 7. Sources of bias in the economic analysis of new drugs.
    Prendergast MM
    JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732927
    [No Abstract]   [Full Text] [Related]  

  • 8. Sources of bias in the economic analysis of new drugs.
    Le Pen C
    JAMA; 2000 Mar; 283(11):1423-4. PubMed ID: 10732926
    [No Abstract]   [Full Text] [Related]  

  • 9. Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations.
    Hartmann M; Knoth H; Schulz D; Knoth S
    Br J Cancer; 2003 Oct; 89(8):1405-8. PubMed ID: 14562007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
    Jang S; Chae YK; Haddad T; Majhail NS
    Breast Cancer Res Treat; 2010 Jun; 121(2):273-9. PubMed ID: 20352486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. News media coverage of medication research: reporting pharmaceutical company funding and use of generic medication names.
    Hochman M; Hochman S; Bor D; McCormick D
    JAMA; 2008 Oct; 300(13):1544-50. PubMed ID: 18827211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conflict of interest in the debate over calcium-channel antagonists.
    Stelfox HT; Chua G; O'Rourke K; Detsky AS
    N Engl J Med; 1998 Jan; 338(2):101-6. PubMed ID: 9420342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflict of interest in industry-sponsored economic evaluations: real or imagined?
    Barbieri M; Drummond MF
    Curr Oncol Rep; 2001 Sep; 3(5):410-3. PubMed ID: 11489241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.
    Perlis RH; Perlis CS; Wu Y; Hwang C; Joseph M; Nierenberg AA
    Am J Psychiatry; 2005 Oct; 162(10):1957-60. PubMed ID: 16199844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industry sponsorship and authorship of clinical trials over 20 years.
    Buchkowsky SS; Jewesson PJ
    Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship.
    Liss H
    Isr Med Assoc J; 2006 Jul; 8(7):451-4. PubMed ID: 16889157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review.
    Sung KH; Chung CY; Lee KM; Lee YK; Lee SY; Lee J; Choi IH; Cho TJ; Yoo WJ; Park MS
    J Pediatr Orthop; 2013; 33(5):494-500. PubMed ID: 23752145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis.
    Krauth D; Anglemyer A; Philipps R; Bero L
    PLoS Biol; 2014 Jan; 12(1):e1001770. PubMed ID: 24465178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.